Opinion|Videos|June 10, 2024
Treatment Resistance in HIV
Paul E. Sax, MD, and Sorana Segal-Maurer, MD, discuss treatment resistance in HIV and how it has changed over the years.
Advertisement
Episodes in this series
BIC = bictegravir
DRV = darunavir
DTG = dolutegravir
F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide
F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate
B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)
DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)
DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)
D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)
DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)
CAB = Cabotegravir
CAB + RPV = Cabotegravir + Rilpivirine
Video content above is prompted by the following question:
- When we are talking about treatment resistance in HIV, what do we mean?
- Impact of drug resistance on the disease course
- Impact on the achievement of global targets
- Most common mutations
- How has resistance in HIV treatment changed over the years?
- FDA approvals have provided options for those with resistance.
Advertisement
Related to this article
Here is a review of glucagon-like peptide-1 receptor agonist use in people with HIV.
In the third episode of the series with Perry N. Halkitis, PhD, MS, MPH, he discusses how human behavior as well as other factors play a significant role in repeating outbreaks.
In the second episode of the series with Perry N. Halkitis, PhD, MS, MPH, he brings his personal experience to this topic and questions whether there should be a shift in who manages the primary care needs of these patients.
The federal agency gave the nod for the smallest once-daily single tablet regimen available for virologically suppressed adults with HIV, including those on complex regimens. The approval is based on the results of the 2 phase 3 ARTISTRY trials.
The federal agency gave the nod to dolutegravir (Tivicay PD), making it the first second-generation integrase inhibitor cleared for children with HIV weighing at least 2 kg, including eligible newborns.
Advertisement
Advertisement
Trending on Contagion Live
1
Ceftriaxone Safety: Separating Signal From Risk
2
Revisiting Whether Cefepime Raises Mortality Risk
3
A Pennsylvania Teen Dies From Rare Measles Neurological Complication
4
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
5